Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
sector : Manufacturing tags : Disease save search
Chemomab Reports New Peer-Reviewed Publication Reinforcing the Clinical Association of Its CCL24 Target with Disease Severity and Mortality in Patients with Systemic Sclerosis
Published: 2024-04-18 (Crawled : 11:00) - globenewswire.com
CMMB | $0.691 -1.29% -1.3% 15K
|
Manufacturing
|
| O: -3.38%
H: 0.0%
C: 0.0%
ccl24 disease association publication sclerosis
IntelGenx Announces First Parkinson’s Disease Patients Dosed with Montelukast VersaFilm® in Phase 2 ‘MONTPARK’ Clinical Trial
Published: 2024-04-08 (Crawled : 12:00) - globenewswire.com
IGXT | $0.17 -19.77% 73K
|
Manufacturing
|
| O: -5.24%
H: 8.65%
C: 8.65%
versafilm first disease montelukast parkinson’s trial
Olink® Insight Unveils Open-access Map of the Human Proteome, Aiding Biomarker Discovery and Understanding of Disease
Published: 2024-04-02 (Crawled : 12:00) - globenewswire.com
OLK | News | $21.85 -1.89% -1.92% 590K
|
Manufacturing
|
| O: 0.13%
H: 0.47%
C: 0.34%
olink disease biomarker
Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma
Published: 2024-03-21 (Crawled : 12:00) - globenewswire.com
LSTA | $2.85 -5.82% 2K
|
Manufacturing
|
| O: 0.32%
H: 9.68%
C: 8.06%
fda rare disease granted treatment designation therapeutics
First Wave BioPharma Announces Two Abstracts on Celiac Disease Research Accepted for Presentation at the 2024 Digestive Disease Week (DDW) Conference
Published: 2024-03-18 (Crawled : 11:00) - globenewswire.com
FWBI | $2.59 -8.8% -9.65% 83K
|
Manufacturing
|
| O: 0.21%
H: 4.21%
C: 2.53%
first conference disease presentation biopharma research week
KidneyIntelX™ included in Final KDIGO 2024 Clinical Guideline for Chronic Kidney Disease (CKD)
Published: 2024-03-14 (Crawled : 11:00) - globenewswire.com
RNLX | $0.785 -2.34% 28K
|
Technology Services
|
| O: 3.23%
H: 13.12%
C: 5.78%
disease kidney
Vaxcyte Completes Enrollment of Phase 2 Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease (IPD) in Infants
Published: 2024-03-04 (Crawled : 13:30) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -0.59%
H: 0.27%
C: -1.83%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -1.85%
H: 0.2%
C: -0.07%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 0.2%
H: 0.18%
C: -0.42%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 0.2%
H: 1.81%
C: -3.43%
vax-24 disease pneumococcal study
Palisade Bio to Present at Digestive Disease Week (DDW) 2024
Published: 2024-02-15 (Crawled : 13:30) - globenewswire.com
PALI | $4.735 -6.61% -7.07% 140K
|
Manufacturing
|
| O: -3.01%
H: 2.99%
C: 1.45%
disease week
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.93 1.3% 0.0% 10M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $66.77 0.92% 0.91% 11M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $144.315 -0.58% -0.59% 700K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
New Case Series Demonstrates Potential of Aquadex Therapy for End-Stage Liver Disease Patients with Fluid Overload
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
NUWE | $0.255 -2.07% -2.12% 230K
|
Manufacturing
|
| O: 6.25%
H: 0.78%
C: -12.75%
aquadex liver disease series potential therapy
Vaxcyte Completes Enrollment of Phase 1/2 Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease (IPD) in Adults Aged 50 and Older
Published: 2024-01-29 (Crawled : 13:30) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: 0.92%
H: 0.76%
C: -1.38%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: -0.55%
H: 1.4%
C: 1.28%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 0.26%
H: 6.59%
C: 6.23%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: -0.43%
H: 6.84%
C: 6.62%
vax-31 disease pneumococcal study
Global Pompe Disease Drugs Market: USD 294.7 Million Growth Forecasted at a CAGR of 4.16% between 2024 to 2028 - Technavio
Published: 2024-01-26 (Crawled : 00:20) - prnewswire.com
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
| Email alert
Add to watchlist
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
| Email alert
Add to watchlist
ALPMF | $9.17 43.47% 16K
|
Health Technology
| Email alert
Add to watchlist
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
| Email alert
Add to watchlist
disease million global growth
Roivant Reports Positive Initial Phase 2 Results for Batoclimab in Graves’ Disease
Published: 2023-12-20 (Crawled : 22:00) - globenewswire.com
ROIV | $10.46 0.97% 0.96% 4.7M
|
Manufacturing
|
| O: 4.52%
H: 2.02%
C: 1.25%
IMVT S | $28.24 -0.28% -0.28% 1.1M
|
Health Technology
|
| O: 11.69%
H: 0.64%
C: -3.24%
disease positive results
Roche Completes Acquisition of Telavant from Roivant, Including Rights to Novel TL1A Directed Antibody (RVT-3101) for the Treatment of Inflammatory Bowel Disease
Published: 2023-12-14 (Crawled : 14:30) - globenewswire.com
ROIV | $10.46 0.97% 0.96% 4.7M
|
Manufacturing
|
| O: 2.22%
H: 1.27%
C: 0.72%
rvt-3101 disease antibody treatment acquisition roche
Alzheimer's Disease Therapeutics Market size to grow by USD 5.41 billion from 2023-2028; North America to account for 39% of market growth - Technavio
Published: 2023-12-12 (Crawled : 20:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: -10.21%
H: 0.0%
C: 0.0%
GIKLY | $4.58 132.75% 820
|
Manufacturing
|
| O: 2.92%
H: 0.0%
C: 0.0%
NVS | $94.36 1.93% 0.0% 2.3M
|
Health Technology
|
| O: 0.71%
H: 0.88%
C: 0.85%
ABBV | $166.41 1.06% 0.0% 5.5M
|
Health Technology
|
| O: -0.17%
H: 1.17%
C: 0.86%
DNLI | $15.98 -3.74% -3.88% 1.5M
|
Health Technology
|
| O: 2.9%
H: 8.82%
C: 8.56%
BIIB | $194.39 2.03% 1.99% 1.6M
|
Health Technology
|
| O: 0.09%
H: 2.58%
C: 2.52%
america disease alzheimer's therapeutics growth market
Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
EWTX | $15.23 -1.42% -1.44% 540K
|
Manufacturing
|
| O: 3.35%
H: 7.88%
C: -6.03%
fda rare drug disease program
Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit
Published: 2023-11-16 (Crawled : 13:00) - globenewswire.com
GRCL | $10.25 -0.29% 6.4M
|
Manufacturing
|
| O: -0.66%
H: 9.76%
C: 4.21%
disease biotechnologies cell therapy
IntelGenx Receives Approval to Conduct ’MONTPARK’ Montelukast VersaFilm® Phase 2 Clinical Trial in Patients with Parkinson's Disease
Published: 2023-11-14 (Crawled : 12:30) - globenewswire.com
IGXT | $0.17 -19.77% 73K
|
Manufacturing
|
| O: 7.74%
H: 1.85%
C: -0.96%
versafilm disease parkinson's approval montelukast trial phase 2
Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease in Adults
Published: 2023-11-09 (Crawled : 13:30) - globenewswire.com
PPRUF | $358.55 37.56% 1.5K
|
Consumer Non-Durables
|
| O: -1.41%
H: 1.77%
C: -1.32%
PPRUY | $36.0023 -0.11% 220K
|
Manufacturing
|
| O: 1.28%
H: 0.21%
C: -1.4%
PCVX | $60.82 0.33% 0.33% 1.3M
|
Health Technology
|
| O: 0.59%
H: 0.63%
C: -5.62%
STRO | $3.635 -3.58% -3.71% 520K
|
Health Technology
|
| O: 4.12%
H: 0.0%
C: -11.07%
vax-31 disease pneumococcal study
Pompe Disease Market to Exhibit Significant Growth by 2032, Predicts DelveInsight | Leading Companies - Asklepios Biopharmaceutical, Inc., Astellas Pharma Inc., Amicus Therapeutics, Sanofi, Spark Therapeutics
Published: 2023-10-26 (Crawled : 21:00) - prnewswire.com
SNYNF | News | $92.7 -2.18% 600K
|
Health Technology
|
| O: -18.18%
H: 0.0%
C: 0.0%
ALPMY | $9.47 -1.11% 520K
|
Manufacturing
|
| O: 4.02%
H: 0.0%
C: -4.32%
SRPT | $115.53 -0.88% -0.9% 640K
|
Health Technology
|
| O: 0.27%
H: 0.0%
C: -4.53%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: -15.73%
H: 0.0%
C: 0.0%
pharma disease companies therapeutics growth market
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
Your saved searches
Save your searches and get alerts when important news are released.